Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study Of ABBV-744 Alone Or In Combination With Ruxolitinib Or Navitoclax In Subjects With Myelofibrosis

NCT04454658 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04454658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04454658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study Of ABBV-744 Alone Or In Combination With Ruxolitinib Or Navitoclax In Subjects With Myelofibrosis
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 11, 2020
Completion date
January 31, 2027
Enrollment
21 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis (mf)